Recent News and Helpful Tips:
Promise of Tetracycline Antibiotic for Osteoarthritis
Study Shows Effectiveness of Doxycycline in Slowing Disease Progression. A tetracycline antibiotic, doxycycline, has been successfully used to treat a wide-range of bacterial infections. In addition to its effects as an antibiotic, doxycycline has other actions as a drug and, in laboratory studies with animals and with human tissue, can inhibit the degradation of cartilage in a way that could be useful for the treatment of osteoarthritis (OA)... click link for more info.
Los Angeles Times Examines Research Surrounding Long-Term Effects of HIV on Brain Tissue
The http://www.latimes.com/features/health/la-he-aidsdementia7nov07,0,146379.story?coll=la-home-healthLos Angeles Times on Monday examined research into the long-term effects of HIV on brain tissue (Brink, Los Angeles Times, 11/7). A study published in October in the Proceedings of the National Academy of Sciences found that HIV can continue to damage some types of brain tissue even when patients are receiving highly active antiretroviral therapy... click link for more info.
Effects of Different Hypocaloric Diets on Protein Secretion From Adipose Tissue of Obese Women
In this study, macronutrient composition, at least the fat and carbohydrate contents, of hypocaloric diets was not of major importance for the outcome of dietary treatment.Diabetes
The many faces of PPARgamma.
Publication Date: 2005 Dec 16 PMID: 16360030Authors: Lehrke, M. - Lazar, M. A.Journal: CellIn an era marked by the increasing prevalence of obesity, diabetes, and cardiovascular disease, the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) has emerged as a transcriptional regulator of metabolism whose activity can be modulated by direct binding of small molecules. As the master regulator of fat-cell formation, PPARgamma is required for the accumulation of adipose tissue and hence contributes to obesity. Yet PPARgamma ligands are clinically effective antidiabetic drugs, although side effects limit their utility. Can PPARgamma be targeted with greater benefit and with less risk to patients? The answer depends upon the basic biology of PPARgamma, and the possibility of selectively modulating the activity of this nuclear receptor in a tissue- and target-gene-specific manner.